<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00679172</url>
  </required_header>
  <id_info>
    <org_study_id>MS01.13</org_study_id>
    <nct_id>NCT00679172</nct_id>
  </id_info>
  <brief_title>Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Single Dose, Dose Escalation Study to Determine the Immunogenicity, Safety and Tolerability of S. Typhi (Ty2 aroC‾ssaV‾) ZH9 at Doses of 5.0 x 10E9 CFU, 7.5 x 10E9 CFU, 1.1 x 10E10 and 1.7 x 10E10 CFU and 1.7 x 10E10 CFU, Following Oral Administration to Healthy, Typhoid Vaccine naïve Subjects in the USA.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emergent BioSolutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emergent BioSolutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the safety, tolerability and immunogenicity of the typhoid fever
      vaccine candidate M01ZH09 manufactured at commercial scale, at a new manufacturing facility.
      The vaccine will be delivered as a single oral dose to healthy, typhoid vaccine-naïve adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomised, double-blind, placebo-controlled, single dose, dose escalation study
      with 4 dosing cohorts. Within each cohort, 45 evaluable subjects were planned (36 subjects
      receiving M01ZH09, 9 receiving placebo).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and Proportion of Subjects Reporting Suspected Unexpected Serious Adverse Reactions.</measure>
    <time_frame>From start of dosing to 28 days post-dosing.</time_frame>
    <description>Number and proportion of subjects reporting suspected unexpected serious adverse reactions (SUSARs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Proportion of Subjects Experiencing Symptomatic Fever.</measure>
    <time_frame>From start of dosing to 14 days post-dosing.</time_frame>
    <description>Number and proportion of subjects experiencing symptomatic (e.g., chills, rigors, sweating, headache, myalgia etc.) elevated body temperature of 38.0°C or more in the 14 days following dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Having Clinically Significant Changes in Laboratory Test Parameters.</measure>
    <time_frame>From start of dosing to 28 days post-dosing.</time_frame>
    <description>Number of subjects having clinically significant changes in clinical laboratory test parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Treatment-related TEAEs.</measure>
    <time_frame>From start of dosing to 28 days post-dosing.</time_frame>
    <description>Number of subjects having TEAEs considered by the principal investigator to be &quot;possibly&quot; or &quot;probably&quot; related to treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Proportion of Subjects Experiencing Bacteraemia.</measure>
    <time_frame>From start of dosing to 28 days post-dosing.</time_frame>
    <description>Number and proportion of subjects experiencing a proven bacteraemia attributed to the vaccine strain S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Having Shedding in Stool of Salmonella Typhi (S. Typhi) (Ty2 aroC‾ssaV‾) ZH9.</measure>
    <time_frame>Beyond 7 days post-dosing through 14 days post-dosing (Cohorts 1-3) or through 21 days post-dosing (Cohort 4).</time_frame>
    <description>Number of subjects having shedding in stool of S. typhi (Ty2 aroC‾ssaV‾) ZH9. Subjects were evaluated beyond Day 14 only in Cohort 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Proportion of Subjects Developing an Immune Response as Determined by the Level of IgG and/or IgA Antibodies for S. Typhi Lipopolysaccharide (LPS).</measure>
    <time_frame>From baseline (pre-dose) to Days 14 or 28 (IgG) or to Days 7 or 14 (IgA).</time_frame>
    <description>Number and proportion of subjects with increase of 70% (fold change of 1.7) in S. typhi LPS-specific serum IgG at Days 14 or 28 AND/OR increase of 50% (fold change of 1.5) in S. typhi LPS-specific serum IgA at Days 7 or 14. Serum IgG and IgA were assayed using enzyme-linked immunosorbent assay (ELISA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and Proportion of Subjects Developing an Immune Response as Determined by the Level of IgA Antibodies for S. Typhi LPS.</measure>
    <time_frame>From baseline (pre-dose) to Days 7 or 14.</time_frame>
    <description>Number and proportion of subjects with increase of 50% (fold change of 1.5) in S. typhi LPS-specific serum IgA at Days 7 or 14. Serum IgA was assayed using ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Proportion of Subjects Developing an Immune Response as Determined by the Level of IgG Antibodies for S. Typhi LPS.</measure>
    <time_frame>From baseline (pre-dose) to Days 14 or 28.</time_frame>
    <description>Number and proportion of subjects with increase of 70% (fold change of 1.7) in S. typhi LPS-specific serum IgG at Days 14 or 28. Serum IgG was assayed using ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Proportion of Subjects Developing an Immune Response as Determined by the Level of IgG Antibodies for S. Typhi LPS.</measure>
    <time_frame>From baseline (pre-dose) to Days 7, 14, or 28.</time_frame>
    <description>Number and proportion of subjects with an increase of 70% (fold change of 1.7) in S. typhi LPS-specific serum IgG at Days 7, 14 or 28. Serum IgG was assayed using ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Proportion of Subjects Developing an Immune Response at the Target Dose of 7.5 x 10^9 CFU (Cohort 2) as Determined by the Number of Antibody Secreting Cells (ASCs) Secreting IgA and/or Fold Change in IgG.</measure>
    <time_frame>At Day 7 (IgA); and from baseline (pre-dose) to Day 28 (IgG).</time_frame>
    <description>Number and proportion of subjects with ≥ 4 ASCs per 10^6 peripheral blood mononuclear cells (PBMCs) at Day 7 secreting IgA specific for S. typhi LPS (detected by enzyme-linked immunospot assay [ELISPOT]) AND/OR 4-fold increase for serum IgG on Day 28 compared to baseline (assay using endpoint titre ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Proportion of Subjects Developing an Immune Response at the Target Dose of 7.5 x 10^9 CFU (Cohort 2) as Determined by the Number of ASCs Secreting IgA.</measure>
    <time_frame>Day 7.</time_frame>
    <description>Number and proportion of subjects with ≥ 4 ASCs per 10^6 PBMCs at Day 7 secreting IgA specific for S. typhi LPS (detected by ELISPOT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Proportion of Subjects Developing an Immune Response at the Target Dose of 7.5 x 10^9 CFU (Cohort 2) as Determined by the Fold Change in IgG.</measure>
    <time_frame>From baseline (pre-dose) to Day 28.</time_frame>
    <description>Number and proportion of subjects with 4-fold increase for serum IgG on Day 28 compared to baseline (assay using endpoint titre ELISA).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">187</enrollment>
  <condition>Typhoid</condition>
  <arm_group>
    <arm_group_label>M01ZH09 Vaccine Candidate Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of 5.0 x 10^9 colony forming units (CFU) S. typhi (Ty2 aroC‾ssaV‾) ZH9 or placebo, administered as a single, oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M01ZH09 Vaccine Candidate Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9 or placebo, administered as a single, oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M01ZH09 Vaccine Candidate Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9 or placebo, administered as a single, oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M01ZH09 Vaccine Candidate Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of of 1.7 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9 or placebo, administered as a single, oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dose of 5.0 x 10^9 CFU (Cohort 1)</intervention_name>
    <description>S. typhi (Ty2 aroC‾ssaV‾) ZH9 live attenuated typhoid vaccine, single dose, oral administration</description>
    <arm_group_label>M01ZH09 Vaccine Candidate Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dose of 7.5 x 10^9 CFU (Cohort 2)</intervention_name>
    <description>S. typhi (Ty2 aroC‾ssaV‾) ZH9 live attenuated typhoid vaccine, single dose, oral administration</description>
    <arm_group_label>M01ZH09 Vaccine Candidate Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dose of 1.1 x 10^10 CFU (Cohort 3)</intervention_name>
    <description>S. typhi (Ty2 aroC‾ssaV‾) ZH9 live attenuated typhoid vaccine, single dose, oral administration</description>
    <arm_group_label>M01ZH09 Vaccine Candidate Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dose of of 1.7 x 10^10 CFU (Cohort 4)</intervention_name>
    <description>S. typhi (Ty2 aroC‾ssaV‾) ZH9 live attenuated typhoid vaccine, single dose, oral administration</description>
    <arm_group_label>M01ZH09 Vaccine Candidate Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (Cohorts 1-4 pooled)</intervention_name>
    <description>Excipients only, single dose, oral administration</description>
    <arm_group_label>M01ZH09 Vaccine Candidate Cohort 1</arm_group_label>
    <arm_group_label>M01ZH09 Vaccine Candidate Cohort 2</arm_group_label>
    <arm_group_label>M01ZH09 Vaccine Candidate Cohort 3</arm_group_label>
    <arm_group_label>M01ZH09 Vaccine Candidate Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy adult subjects aged 18 to 50 years inclusive, who are able and willing to give
             informed consent, following a detailed explanation of participation in protocol

          -  available for the duration of the study and available for scheduled and potential
             additional visits

        Exclusion Criteria:

          -  women who are pregnant, breast-feeding or of childbearing potential and unwilling to
             use a reliable method of contraception throughout the study period

          -  history of anaphylactic shock following vaccination by any route have phenylketonuria

          -  hypersensitivity to any component of the vaccine or are hypersensitive to two of the
             following antibiotics: ciprofloxacin, azithromycin, ampicillin, trimethoprim
             sulfamethoxazole

          -  received antibiotic medication within 14 days prior to dosing

          -  received any vaccine within 4 weeks prior to dosing or plan to receive a vaccine
             within 4 weeks after dosing

          -  received any vaccine against Salmonella typhi (licensed or investigational) or ever
             suffered from typhoid fever

          -  subjects who test positive for hepatitis B, hepatitis C, HIV or human leucocyte
             antigen B-27

          -  known or suspected history of liver or active gall bladder disease, ongoing
             gastro-intestinal disease or abnormality

          -  commercial food handlers or health care workers with direct contact with high risk
             patients or who have household contacts with immuno-compromised individuals, pregnant
             women or children less than 2 years of age

          -  subjects who have a clinically significant amount of protein or haemoglobin in their
             urine or abnormality of their haematology or serum biochemistry parameters

          -  impairment of immune function or those receiving or have received cytotoxic drugs in
             the 6 months prior to study entry

          -  subjects who use antacids, proton pump inhibitors or H2 blockers on a regular basis or
             have consumed proton pump inhibitors or H2 blockers within 24 hours prior to dosing

          -  acute infections (including fever of 37.5 degrees Celsius or greater) on the day of
             dosing.

          -  subjects with chronic disease (e.g Crohn's disease, inflammatory bowel disease,
             diabetes) who cannot withstand a 3 hour fast

          -  substance abuse or a history of substance abuse that might interfere with
             participation in the study

          -  body mass index (BMI) is less than 19 or greater than 34 kg per m2

          -  clinically significant medical condition that precludes participation in the study

          -  subjects who have participated in an interventional clinical trial within 60 days of
             dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Lockhart, DM</last_name>
    <role>Study Director</role>
    <affiliation>Emergent BioSolutions</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins Bloomberg School of Public Health</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unit of Infectious Diseases, University of Vermont College of Medicine</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lyon CE, Sadigh KS, Carmolli MP, Harro C, Sheldon E, Lindow JC, Larsson CJ, Martinez T, Feller A, Ventrone CH, Sack DA, DeNearing B, Fingar A, Pierce K, Dill EA, Schwartz HI, Beardsworth EE, Kilonzo B, May JP, Lam W, Upton A, Budhram R, Kirkpatrick BD. In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units. Vaccine. 2010 Apr 30;28(20):3602-8. doi: 10.1016/j.vaccine.2010.02.017. Epub 2010 Feb 24.</citation>
    <PMID>20188175</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2008</study_first_submitted>
  <study_first_submitted_qc>May 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2008</study_first_posted>
  <results_first_submitted>May 2, 2017</results_first_submitted>
  <results_first_submitted_qc>June 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 7, 2017</results_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Typhoid Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>M01ZH09 Vaccine Candidate Cohort 1</title>
          <description>Dose of 5.0 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
        </group>
        <group group_id="P2">
          <title>M01ZH09 Vaccine Candidate Cohort 2</title>
          <description>Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
        </group>
        <group group_id="P3">
          <title>M01ZH09 Vaccine Candidate Cohort 3</title>
          <description>Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
        </group>
        <group group_id="P4">
          <title>M01ZH09 Vaccine Candidate Cohort 4</title>
          <description>Dose of 1.7 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
        </group>
        <group group_id="P5">
          <title>Pooled Placebo</title>
          <description>Placebo comparator comprised of excipients only, pooled across Cohorts 1-4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="39"/>
                <participants group_id="P5" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="38"/>
                <participants group_id="P5" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>M01ZH09 Vaccine Candidate Cohort 1</title>
          <description>Dose of 5.0 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
        </group>
        <group group_id="B2">
          <title>M01ZH09 Vaccine Candidate Cohort 2</title>
          <description>Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
        </group>
        <group group_id="B3">
          <title>M01ZH09 Vaccine Candidate Cohort 3</title>
          <description>Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
        </group>
        <group group_id="B4">
          <title>M01ZH09 Vaccine Candidate Cohort 4</title>
          <description>Dose of 1.7 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
        </group>
        <group group_id="B5">
          <title>Pooled Placebo</title>
          <description>Placebo comparator comprised of excipients only, pooled across Cohorts 1-4.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="36"/>
            <count group_id="B4" value="39"/>
            <count group_id="B5" value="37"/>
            <count group_id="B6" value="187"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="183"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.2" spread="10.13"/>
                    <measurement group_id="B2" value="33.1" spread="10.00"/>
                    <measurement group_id="B3" value="32.0" spread="9.99"/>
                    <measurement group_id="B4" value="31.3" spread="9.21"/>
                    <measurement group_id="B5" value="32.3" spread="10.01"/>
                    <measurement group_id="B6" value="32.4" spread="9.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number and Proportion of Subjects Reporting Suspected Unexpected Serious Adverse Reactions.</title>
        <description>Number and proportion of subjects reporting suspected unexpected serious adverse reactions (SUSARs).</description>
        <time_frame>From start of dosing to 28 days post-dosing.</time_frame>
        <population>Safety Population: All subjects who received a dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>M01ZH09 Vaccine Candidate Cohort 1</title>
            <description>Dose of 5.0 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O2">
            <title>M01ZH09 Vaccine Candidate Cohort 2</title>
            <description>Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O3">
            <title>M01ZH09 Vaccine Candidate Cohort 3</title>
            <description>Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O4">
            <title>M01ZH09 Vaccine Candidate Cohort 4</title>
            <description>Dose of 1.7 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O5">
            <title>Pooled Placebo</title>
            <description>Placebo comparator comprised of excipients only, pooled across Cohorts 1-4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Proportion of Subjects Reporting Suspected Unexpected Serious Adverse Reactions.</title>
          <description>Number and proportion of subjects reporting suspected unexpected serious adverse reactions (SUSARs).</description>
          <population>Safety Population: All subjects who received a dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number and Proportion of Subjects Experiencing Symptomatic Fever.</title>
        <description>Number and proportion of subjects experiencing symptomatic (e.g., chills, rigors, sweating, headache, myalgia etc.) elevated body temperature of 38.0°C or more in the 14 days following dosing.</description>
        <time_frame>From start of dosing to 14 days post-dosing.</time_frame>
        <population>Safety Population: All subjects who received a dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>M01ZH09 Vaccine Candidate Cohort 1</title>
            <description>Dose of 5.0 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O2">
            <title>M01ZH09 Vaccine Candidate Cohort 2</title>
            <description>Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O3">
            <title>M01ZH09 Vaccine Candidate Cohort 3</title>
            <description>Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O4">
            <title>M01ZH09 Vaccine Candidate Cohort 4</title>
            <description>Dose of 1.7 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O5">
            <title>Pooled Placebo</title>
            <description>Placebo comparator comprised of excipients only, pooled across Cohorts 1-4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Proportion of Subjects Experiencing Symptomatic Fever.</title>
          <description>Number and proportion of subjects experiencing symptomatic (e.g., chills, rigors, sweating, headache, myalgia etc.) elevated body temperature of 38.0°C or more in the 14 days following dosing.</description>
          <population>Safety Population: All subjects who received a dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Having Clinically Significant Changes in Laboratory Test Parameters.</title>
        <description>Number of subjects having clinically significant changes in clinical laboratory test parameters.</description>
        <time_frame>From start of dosing to 28 days post-dosing.</time_frame>
        <population>Safety Population: All subjects who received a dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>M01ZH09 Vaccine Candidate Cohort 1</title>
            <description>Dose of 5.0 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O2">
            <title>M01ZH09 Vaccine Candidate Cohort 2</title>
            <description>Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O3">
            <title>M01ZH09 Vaccine Candidate Cohort 3</title>
            <description>Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O4">
            <title>M01ZH09 Vaccine Candidate Cohort 4</title>
            <description>Dose of 1.7 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O5">
            <title>Pooled Placebo</title>
            <description>Placebo comparator comprised of excipients only, pooled across Cohorts 1-4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Having Clinically Significant Changes in Laboratory Test Parameters.</title>
          <description>Number of subjects having clinically significant changes in clinical laboratory test parameters.</description>
          <population>Safety Population: All subjects who received a dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alanine aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haematocrit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Treatment-related TEAEs.</title>
        <description>Number of subjects having TEAEs considered by the principal investigator to be &quot;possibly&quot; or &quot;probably&quot; related to treatment.</description>
        <time_frame>From start of dosing to 28 days post-dosing.</time_frame>
        <population>Safety Population: All subjects who received a dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>M01ZH09 Vaccine Candidate Cohort 1</title>
            <description>Dose of 5.0 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O2">
            <title>M01ZH09 Vaccine Candidate Cohort 2</title>
            <description>Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O3">
            <title>M01ZH09 Vaccine Candidate Cohort 3</title>
            <description>Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O4">
            <title>M01ZH09 Vaccine Candidate Cohort 4</title>
            <description>Dose of 1.7 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O5">
            <title>Pooled Placebo</title>
            <description>Placebo comparator comprised of excipients only, pooled across Cohorts 1-4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Treatment-related TEAEs.</title>
          <description>Number of subjects having TEAEs considered by the principal investigator to be &quot;possibly&quot; or &quot;probably&quot; related to treatment.</description>
          <population>Safety Population: All subjects who received a dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with possibly related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with probably related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number and Proportion of Subjects Experiencing Bacteraemia.</title>
        <description>Number and proportion of subjects experiencing a proven bacteraemia attributed to the vaccine strain S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
        <time_frame>From start of dosing to 28 days post-dosing.</time_frame>
        <population>Safety Population: All subjects who received a dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>M01ZH09 Vaccine Candidate Cohort 1</title>
            <description>Dose of 5.0 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O2">
            <title>M01ZH09 Vaccine Candidate Cohort 2</title>
            <description>Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O3">
            <title>M01ZH09 Vaccine Candidate Cohort 3</title>
            <description>Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O4">
            <title>M01ZH09 Vaccine Candidate Cohort 4</title>
            <description>Dose of 1.7 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O5">
            <title>Pooled Placebo</title>
            <description>Placebo comparator comprised of excipients only, pooled across Cohorts 1-4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Proportion of Subjects Experiencing Bacteraemia.</title>
          <description>Number and proportion of subjects experiencing a proven bacteraemia attributed to the vaccine strain S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          <population>Safety Population: All subjects who received a dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Having Shedding in Stool of Salmonella Typhi (S. Typhi) (Ty2 aroC‾ssaV‾) ZH9.</title>
        <description>Number of subjects having shedding in stool of S. typhi (Ty2 aroC‾ssaV‾) ZH9. Subjects were evaluated beyond Day 14 only in Cohort 4.</description>
        <time_frame>Beyond 7 days post-dosing through 14 days post-dosing (Cohorts 1-3) or through 21 days post-dosing (Cohort 4).</time_frame>
        <population>Safety Population: All subjects who received a dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>M01ZH09 Vaccine Candidate Cohort 1</title>
            <description>Dose of 5.0 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O2">
            <title>M01ZH09 Vaccine Candidate Cohort 2</title>
            <description>Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O3">
            <title>M01ZH09 Vaccine Candidate Cohort 3</title>
            <description>Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O4">
            <title>M01ZH09 Vaccine Candidate Cohort 4</title>
            <description>Dose of 1.7 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O5">
            <title>Pooled Placebo</title>
            <description>Placebo comparator comprised of excipients only, pooled across Cohorts 1-4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Having Shedding in Stool of Salmonella Typhi (S. Typhi) (Ty2 aroC‾ssaV‾) ZH9.</title>
          <description>Number of subjects having shedding in stool of S. typhi (Ty2 aroC‾ssaV‾) ZH9. Subjects were evaluated beyond Day 14 only in Cohort 4.</description>
          <population>Safety Population: All subjects who received a dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number and Proportion of Subjects Developing an Immune Response as Determined by the Level of IgG and/or IgA Antibodies for S. Typhi Lipopolysaccharide (LPS).</title>
        <description>Number and proportion of subjects with increase of 70% (fold change of 1.7) in S. typhi LPS-specific serum IgG at Days 14 or 28 AND/OR increase of 50% (fold change of 1.5) in S. typhi LPS-specific serum IgA at Days 7 or 14. Serum IgG and IgA were assayed using enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>From baseline (pre-dose) to Days 14 or 28 (IgG) or to Days 7 or 14 (IgA).</time_frame>
        <population>ITT Population: all subjects who received study medication and had any postbaseline immunogenicity data available up to and including Day 28.</population>
        <group_list>
          <group group_id="O1">
            <title>M01ZH09 Vaccine Candidate Cohort 1</title>
            <description>Dose of 5.0 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O2">
            <title>M01ZH09 Vaccine Candidate Cohort 2</title>
            <description>Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O3">
            <title>M01ZH09 Vaccine Candidate Cohort 3</title>
            <description>Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O4">
            <title>M01ZH09 Vaccine Candidate Cohort 4</title>
            <description>Dose of 1.7 x 10^10 CFU S. typhi (Ty2 aroC- ssaV-) ZH9.</description>
          </group>
          <group group_id="O5">
            <title>Pooled Placebo</title>
            <description>Placebo comparator comprised of excipients only, pooled across Cohorts 1-4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Proportion of Subjects Developing an Immune Response as Determined by the Level of IgG and/or IgA Antibodies for S. Typhi Lipopolysaccharide (LPS).</title>
          <description>Number and proportion of subjects with increase of 70% (fold change of 1.7) in S. typhi LPS-specific serum IgG at Days 14 or 28 AND/OR increase of 50% (fold change of 1.5) in S. typhi LPS-specific serum IgA at Days 7 or 14. Serum IgG and IgA were assayed using enzyme-linked immunosorbent assay (ELISA).</description>
          <population>ITT Population: all subjects who received study medication and had any postbaseline immunogenicity data available up to and including Day 28.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Proportion of Subjects Developing an Immune Response as Determined by the Level of IgA Antibodies for S. Typhi LPS.</title>
        <description>Number and proportion of subjects with increase of 50% (fold change of 1.5) in S. typhi LPS-specific serum IgA at Days 7 or 14. Serum IgA was assayed using ELISA.</description>
        <time_frame>From baseline (pre-dose) to Days 7 or 14.</time_frame>
        <population>ITT Population: all subjects who received study medication and had any postbaseline immunogenicity data available up to and including Day 28.</population>
        <group_list>
          <group group_id="O1">
            <title>M01ZH09 Vaccine Candidate Cohort 1</title>
            <description>Dose of 5.0 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O2">
            <title>M01ZH09 Vaccine Candidate Cohort 2</title>
            <description>Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O3">
            <title>M01ZH09 Vaccine Candidate Cohort 3</title>
            <description>Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O4">
            <title>M01ZH09 Vaccine Candidate Cohort 4</title>
            <description>Dose of 1.7 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O5">
            <title>Pooled Placebo</title>
            <description>Placebo comparator comprised of excipients only, pooled across Cohorts 1-4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Proportion of Subjects Developing an Immune Response as Determined by the Level of IgA Antibodies for S. Typhi LPS.</title>
          <description>Number and proportion of subjects with increase of 50% (fold change of 1.5) in S. typhi LPS-specific serum IgA at Days 7 or 14. Serum IgA was assayed using ELISA.</description>
          <population>ITT Population: all subjects who received study medication and had any postbaseline immunogenicity data available up to and including Day 28.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Proportion of Subjects Developing an Immune Response as Determined by the Level of IgG Antibodies for S. Typhi LPS.</title>
        <description>Number and proportion of subjects with increase of 70% (fold change of 1.7) in S. typhi LPS-specific serum IgG at Days 14 or 28. Serum IgG was assayed using ELISA.</description>
        <time_frame>From baseline (pre-dose) to Days 14 or 28.</time_frame>
        <population>ITT Population: all subjects who received study medication and had any postbaseline immunogenicity data available up to and including Day 28.</population>
        <group_list>
          <group group_id="O1">
            <title>M01ZH09 Vaccine Candidate Cohort 1</title>
            <description>Dose of 5.0 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O2">
            <title>M01ZH09 Vaccine Candidate Cohort 2</title>
            <description>Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O3">
            <title>M01ZH09 Vaccine Candidate Cohort 3</title>
            <description>Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O4">
            <title>M01ZH09 Vaccine Candidate Cohort 4</title>
            <description>Dose of 1.7 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O5">
            <title>Pooled Placebo</title>
            <description>Placebo comparator comprised of excipients only, pooled across Cohorts 1-4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Proportion of Subjects Developing an Immune Response as Determined by the Level of IgG Antibodies for S. Typhi LPS.</title>
          <description>Number and proportion of subjects with increase of 70% (fold change of 1.7) in S. typhi LPS-specific serum IgG at Days 14 or 28. Serum IgG was assayed using ELISA.</description>
          <population>ITT Population: all subjects who received study medication and had any postbaseline immunogenicity data available up to and including Day 28.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Proportion of Subjects Developing an Immune Response as Determined by the Level of IgG Antibodies for S. Typhi LPS.</title>
        <description>Number and proportion of subjects with an increase of 70% (fold change of 1.7) in S. typhi LPS-specific serum IgG at Days 7, 14 or 28. Serum IgG was assayed using ELISA.</description>
        <time_frame>From baseline (pre-dose) to Days 7, 14, or 28.</time_frame>
        <population>ITT Population: all subjects who received study medication and had any postbaseline immunogenicity data available up to and including Day 14.</population>
        <group_list>
          <group group_id="O1">
            <title>M01ZH09 Vaccine Candidate Cohort 1</title>
            <description>Dose of 5.0 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O2">
            <title>M01ZH09 Vaccine Candidate Cohort 2</title>
            <description>Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O3">
            <title>M01ZH09 Vaccine Candidate Cohort 3</title>
            <description>Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O4">
            <title>M01ZH09 Vaccine Candidate Cohort 4</title>
            <description>Dose of 1.7 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O5">
            <title>Pooled Placebo</title>
            <description>Placebo comparator comprised of excipients only, pooled across Cohorts 1-4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Proportion of Subjects Developing an Immune Response as Determined by the Level of IgG Antibodies for S. Typhi LPS.</title>
          <description>Number and proportion of subjects with an increase of 70% (fold change of 1.7) in S. typhi LPS-specific serum IgG at Days 7, 14 or 28. Serum IgG was assayed using ELISA.</description>
          <population>ITT Population: all subjects who received study medication and had any postbaseline immunogenicity data available up to and including Day 14.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Proportion of Subjects Developing an Immune Response at the Target Dose of 7.5 x 10^9 CFU (Cohort 2) as Determined by the Number of Antibody Secreting Cells (ASCs) Secreting IgA and/or Fold Change in IgG.</title>
        <description>Number and proportion of subjects with ≥ 4 ASCs per 10^6 peripheral blood mononuclear cells (PBMCs) at Day 7 secreting IgA specific for S. typhi LPS (detected by enzyme-linked immunospot assay [ELISPOT]) AND/OR 4-fold increase for serum IgG on Day 28 compared to baseline (assay using endpoint titre ELISA).</description>
        <time_frame>At Day 7 (IgA); and from baseline (pre-dose) to Day 28 (IgG).</time_frame>
        <population>ITT Population (Cohort 2): all subjects who received study medication and had any postbaseline immunogenicity data available up to and including Day 28.</population>
        <group_list>
          <group group_id="O1">
            <title>M01ZH09 Vaccine Candidate Cohort 2</title>
            <description>Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Cohort 2</title>
            <description>Placebo comparator comprised of excipients only - Cohort 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Proportion of Subjects Developing an Immune Response at the Target Dose of 7.5 x 10^9 CFU (Cohort 2) as Determined by the Number of Antibody Secreting Cells (ASCs) Secreting IgA and/or Fold Change in IgG.</title>
          <description>Number and proportion of subjects with ≥ 4 ASCs per 10^6 peripheral blood mononuclear cells (PBMCs) at Day 7 secreting IgA specific for S. typhi LPS (detected by enzyme-linked immunospot assay [ELISPOT]) AND/OR 4-fold increase for serum IgG on Day 28 compared to baseline (assay using endpoint titre ELISA).</description>
          <population>ITT Population (Cohort 2): all subjects who received study medication and had any postbaseline immunogenicity data available up to and including Day 28.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Proportion of Subjects Developing an Immune Response at the Target Dose of 7.5 x 10^9 CFU (Cohort 2) as Determined by the Number of ASCs Secreting IgA.</title>
        <description>Number and proportion of subjects with ≥ 4 ASCs per 10^6 PBMCs at Day 7 secreting IgA specific for S. typhi LPS (detected by ELISPOT).</description>
        <time_frame>Day 7.</time_frame>
        <population>ITT Population (Cohort 2): all subjects who received study medication and had any postbaseline immunogenicity data available up to and including Day 28.</population>
        <group_list>
          <group group_id="O1">
            <title>M01ZH09 Vaccine Candidate Cohort 2</title>
            <description>Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Cohort 2</title>
            <description>Placebo comparator comprised of excipients only - Cohort 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Proportion of Subjects Developing an Immune Response at the Target Dose of 7.5 x 10^9 CFU (Cohort 2) as Determined by the Number of ASCs Secreting IgA.</title>
          <description>Number and proportion of subjects with ≥ 4 ASCs per 10^6 PBMCs at Day 7 secreting IgA specific for S. typhi LPS (detected by ELISPOT).</description>
          <population>ITT Population (Cohort 2): all subjects who received study medication and had any postbaseline immunogenicity data available up to and including Day 28.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Proportion of Subjects Developing an Immune Response at the Target Dose of 7.5 x 10^9 CFU (Cohort 2) as Determined by the Fold Change in IgG.</title>
        <description>Number and proportion of subjects with 4-fold increase for serum IgG on Day 28 compared to baseline (assay using endpoint titre ELISA).</description>
        <time_frame>From baseline (pre-dose) to Day 28.</time_frame>
        <population>ITT Population (Cohort 2): all subjects who received study medication and had any postbaseline immunogenicity data available up to and including Day 28.</population>
        <group_list>
          <group group_id="O1">
            <title>M01ZH09 Vaccine Candidate Cohort 2</title>
            <description>Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Cohort 2</title>
            <description>Placebo comparator comprised of excipients only - Cohort 2</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Proportion of Subjects Developing an Immune Response at the Target Dose of 7.5 x 10^9 CFU (Cohort 2) as Determined by the Fold Change in IgG.</title>
          <description>Number and proportion of subjects with 4-fold increase for serum IgG on Day 28 compared to baseline (assay using endpoint titre ELISA).</description>
          <population>ITT Population (Cohort 2): all subjects who received study medication and had any postbaseline immunogenicity data available up to and including Day 28.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 28.</time_frame>
      <desc>Treatment-emergent adverse events (TEAEs) are defined as those adverse events which occurred postdose or which were present predose and became worse postdose. The proportions of subjects reported TEAEs and SAEs were pre-defined safety outcome variables.</desc>
      <group_list>
        <group group_id="E1">
          <title>M01ZH09 Vaccine Candidate Cohort 1</title>
          <description>Dose of 5.0 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
        </group>
        <group group_id="E2">
          <title>M01ZH09 Vaccine Candidate Cohort 2</title>
          <description>Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
        </group>
        <group group_id="E3">
          <title>M01ZH09 Vaccine Candidate Cohort 3</title>
          <description>Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
        </group>
        <group group_id="E4">
          <title>M01ZH09 Vaccine Candidate Cohort 4</title>
          <description>Dose of 1.7 x 10^10 CFU S. typhi (Ty2 aroC‾ssaV‾) ZH9.</description>
        </group>
        <group group_id="E5">
          <title>Pooled Placebo</title>
          <description>Placebo comparator comprised of excipients only, pooled across Cohorts 1-4.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Culture stool positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any proposed publication was subject to review conditions and timelines agreed between Emergent Product Development UK Ltd and the site Principal Investigator and detailed in the agreements with these parties prior to the start of the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Tim Babinchak</name_or_title>
      <organization>Emergent Product Development Gaithersburg</organization>
      <phone>(240) 631-3585</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

